BRPI0415505A - agente terapêutico para mesotelioma - Google Patents

agente terapêutico para mesotelioma

Info

Publication number
BRPI0415505A
BRPI0415505A BRPI0415505-0A BRPI0415505A BRPI0415505A BR PI0415505 A BRPI0415505 A BR PI0415505A BR PI0415505 A BRPI0415505 A BR PI0415505A BR PI0415505 A BRPI0415505 A BR PI0415505A
Authority
BR
Brazil
Prior art keywords
therapeutic agent
mesothelioma
mesothelioma therapeutic
interleukin
antagonist
Prior art date
Application number
BRPI0415505-0A
Other languages
English (en)
Inventor
Norihiro Nishimoto
Tadamitsu Kishimoto
Yasuo Adachi
Koichi Takayama
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34463281&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415505(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BRPI0415505A publication Critical patent/BRPI0415505A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mobile Radio Communication Systems (AREA)

Abstract

"AGENTE TERAPêUTICO PARA MESOTELIOMA". A presente invenção proporciona um agente terapêutico para mesotelioma que contém um antagonista de interleucina-6 (IL-6) tal como anticorpo para receptor de IL-6 (IL-6R), e um inibidor de crescimento celular de mesotelioma que contém um antagonista de IL-6 tal como anticorpo para IL-6R.
BRPI0415505-0A 2003-10-17 2004-10-15 agente terapêutico para mesotelioma BRPI0415505A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003358152 2003-10-17
PCT/JP2004/015674 WO2005037315A1 (ja) 2003-10-17 2004-10-15 中皮腫治療剤

Publications (1)

Publication Number Publication Date
BRPI0415505A true BRPI0415505A (pt) 2006-12-12

Family

ID=34463281

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415505-0A BRPI0415505A (pt) 2003-10-17 2004-10-15 agente terapêutico para mesotelioma

Country Status (23)

Country Link
US (2) US20070134242A1 (pt)
EP (1) EP1690550B1 (pt)
JP (1) JP4651541B2 (pt)
KR (1) KR101193708B1 (pt)
CN (1) CN1874790B (pt)
AR (1) AR046290A1 (pt)
AU (1) AU2004281139B2 (pt)
BR (1) BRPI0415505A (pt)
CA (1) CA2542691C (pt)
DK (1) DK1690550T3 (pt)
ES (1) ES2392824T3 (pt)
HK (1) HK1096588A1 (pt)
IL (1) IL174909A (pt)
MX (1) MXPA06003768A (pt)
MY (1) MY149856A (pt)
NO (1) NO20061906L (pt)
NZ (1) NZ546557A (pt)
PL (1) PL1690550T3 (pt)
RU (2) RU2392967C2 (pt)
SI (1) SI1690550T1 (pt)
TW (1) TWI350175B (pt)
WO (1) WO2005037315A1 (pt)
ZA (1) ZA200602973B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2284271C (en) 1997-03-21 2012-05-08 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
KR20110091822A (ko) * 2002-02-14 2011-08-12 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP3736295A1 (en) 2004-03-24 2020-11-11 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
EP1941907B1 (en) 2005-10-14 2016-03-23 Fukuoka University Inhibitor of transplanted islet dysfunction in islet transplantation
BRPI0617664B8 (pt) 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP3135298B1 (en) * 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
ES2564392T3 (es) 2007-01-23 2016-03-22 Shinshu University Inhibidores de IL-6 para el tratamiento de rechazo crónico
US8252286B2 (en) * 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
JP5859202B2 (ja) * 2007-05-21 2016-02-10 アルダーバイオ・ホールディングズ・エルエルシー 新規のウサギ抗体ヒト化方法及びヒト化ウサギ抗体
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8062864B2 (en) * 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
HUE043782T2 (hu) 2007-05-21 2019-09-30 Alderbio Holdings Llc IL-6 elleni antitestek és alkalmazásuk
EP4368721A2 (en) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
AR068563A1 (es) 2007-09-26 2009-11-18 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo mutante
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
MY195714A (en) 2008-04-11 2023-02-07 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable of Binding to Two or More Antigen Molecules Repeatedly
CN102256623A (zh) 2008-06-05 2011-11-23 独立行政法人国立癌症研究中心 神经浸润抑制剂
WO2010013846A1 (ja) * 2008-07-30 2010-02-04 国立大学法人岡山大学 新規悪性中皮腫治療剤及び免疫賦活化剤
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
AU2009323009B2 (en) * 2008-11-25 2016-01-28 Vitaeris Inc. Antibodies to IL-6 and use thereof
US20120183539A1 (en) * 2009-07-31 2012-07-19 Shin Maeda Cancer Metastasis Inhibitor
SI2493922T1 (sl) 2009-10-26 2017-06-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo glikoziliranega imunoglobulina
MX2012005927A (es) 2009-11-24 2012-11-23 Alder Biopharmaceuticals Inc Anticuerpos para il-6 uso de los mismos.
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
RS63800B1 (sr) * 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
US20130123138A1 (en) * 2010-07-25 2013-05-16 New York University Compositions and methods for prognosis of mesothelioma
EP2638067A2 (en) 2010-11-08 2013-09-18 Genentech, Inc. Subcutaneously administered anti-il-6 receptor antibody
ES2847891T3 (es) 2010-11-23 2021-08-04 Vitaeris Inc Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
KR102385507B1 (ko) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
CA2827581A1 (en) * 2011-03-03 2012-09-07 Apexigen, Inc. Anti-il-6 receptor antibodies and methods of use
PL3446714T3 (pl) 2011-06-02 2021-11-22 University Of Louisville Research Foundation, Inc. Nanocząstki sprzężone z cząsteczką skierowaną przeciwko nukleolinie
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
JO3370B1 (ar) 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
KR20150090107A (ko) 2012-12-06 2015-08-05 도쿠리츠다이가쿠호징 가나자와다이가쿠 중피종의 치료 방법
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
RU2674996C2 (ru) 2013-07-04 2018-12-14 Ф. Хоффманн-Ля Рош Аг Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки
KR101892883B1 (ko) 2015-02-27 2018-10-05 추가이 세이야쿠 가부시키가이샤 Il-6 관련 질환 치료용 조성물
CA3020885A1 (en) 2015-05-05 2016-11-10 Mohammad Tariq MALIK Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
PL3299810T3 (pl) 2015-05-19 2021-12-13 National Center Of Neurology And Psychiatry Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm)
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
AU2018234844B2 (en) 2017-03-17 2024-01-25 Ohio State Innovation Foundation Nanoparticles for delivery of chemopreventive agents
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US521628A (en) 1894-06-19 Housekeeping-cabinet
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
JP2914672B2 (ja) 1989-01-17 1999-07-05 中外製薬株式会社 Ｂｓｆ▲下２▼アンタゴニスト
ATE144713T1 (de) * 1989-07-20 1996-11-15 Tadamitsu Kishimoto Antikörper gegen menschlichen interleukin-6- rezeptor
JP2898040B2 (ja) 1990-01-26 1999-05-31 忠三 岸本 ｇｐ１３０蛋白質に対する抗体
US5210075A (en) 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
DE69229482T2 (de) 1991-04-25 1999-11-18 Chugai Pharmaceutical Co Ltd Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en) 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
JPH07324097A (ja) 1994-05-30 1995-12-12 Daicel Chem Ind Ltd インターロイキン６拮抗剤、及びペプチド類または医薬として許容されるその塩類
PL182089B1 (en) 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
IT1274350B (it) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
IT1274782B (it) 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
JPH08245414A (ja) 1995-01-27 1996-09-24 Private Biolog Corp Ｉｌ−６関連疾患の治療用組成物および方法
FR2733250B1 (fr) 1995-04-21 1997-07-04 Diaclone Anticorps monoclonaux anti-gp130, et leurs utilisations
JPH08311098A (ja) 1995-05-22 1996-11-26 Daicel Chem Ind Ltd 新規ペプチド類およびそれを含有するインターロイキン６拮抗剤
US5571513A (en) 1995-05-31 1996-11-05 The Board Of Regents Of The University Of Oklahoma Anti-gp130 monoclonal antibodies
AU6038196A (en) * 1995-06-07 1996-12-30 Private Biologicals Corporation Compositions and methods of treating il-6 associated disease s
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
CZ297083B6 (cs) 1998-03-17 2006-09-13 Chugai Seiyaku Kabushiki Kaisha Cinidlo pro prevenci a lécbu zánetlivého onemocnení streva obsahující aktivní slozku antagonistu IL-6
EP1244807A1 (en) * 1999-12-09 2002-10-02 Human Genome Sciences, Inc. Il-6 like polynucleotide
WO2002034292A1 (fr) 2000-10-25 2002-05-02 Chugai Seiyaku Kabushiki Kaisha Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active
AU2000279625A1 (en) * 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
US20050090453A1 (en) * 2003-01-15 2005-04-28 Solbec Pharmaceuticals Co., Ltd. Methods of modulating IL-6
AU2004204261A1 (en) * 2003-01-15 2004-07-29 Solbec Pharmaceuticals Limited Method of modulating IL-6
JP2006516617A (ja) * 2003-02-04 2006-07-06 セントコア・インコーポレイテッド アポトーシスを増強させるための、ｉｌ−６アンタゴニストとステロイドの併用
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US20060094645A1 (en) * 2004-10-06 2006-05-04 Oliver Lawless Method for defining and treating chemically-induced immune disorders using tumor necrosis factor (TFNalpha), interleukin-1 (lL-1), and interleulin-6R(lL-6R) antagonists

Also Published As

Publication number Publication date
CA2542691A1 (en) 2005-04-28
US20080274106A1 (en) 2008-11-06
MXPA06003768A (es) 2006-06-23
CN1874790B (zh) 2011-11-16
IL174909A (en) 2010-11-30
CN1874790A (zh) 2006-12-06
NZ546557A (en) 2010-01-29
AU2004281139B2 (en) 2011-01-20
IL174909A0 (en) 2006-08-20
CA2542691C (en) 2013-09-24
RU2554942C2 (ru) 2015-07-10
AU2004281139A1 (en) 2005-04-28
DK1690550T3 (da) 2012-11-05
PL1690550T3 (pl) 2013-01-31
TWI350175B (en) 2011-10-11
TW200517126A (en) 2005-06-01
KR20070029632A (ko) 2007-03-14
US20070134242A1 (en) 2007-06-14
EP1690550A4 (en) 2009-07-15
ES2392824T3 (es) 2012-12-14
SI1690550T1 (sl) 2012-12-31
JPWO2005037315A1 (ja) 2006-12-28
EP1690550B1 (en) 2012-08-08
WO2005037315A1 (ja) 2005-04-28
JP4651541B2 (ja) 2011-03-16
RU2006116896A (ru) 2007-12-10
EP1690550A1 (en) 2006-08-16
AR046290A1 (es) 2005-11-30
MY149856A (en) 2013-10-31
US8802092B2 (en) 2014-08-12
KR101193708B1 (ko) 2012-10-22
NO20061906L (no) 2006-06-21
HK1096588A1 (en) 2007-06-08
RU2010102911A (ru) 2011-08-10
RU2392967C2 (ru) 2010-06-27
ZA200602973B (en) 2007-07-25

Similar Documents

Publication Publication Date Title
BRPI0415505A (pt) agente terapêutico para mesotelioma
IL273422A (en) Methods and systems for extracorporeal organ treatment
CL2008002207A1 (es) Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04).
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
BRPI0817482B8 (pt) uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
SG166788A1 (en) Use of b cell expansion agents in generating antibodies
IL181473A0 (en) Humanized anti-beta 7 antagonists and uses therefor
BRPI0417072B8 (pt) "uso de antagonista de interleucina-6 (il-6)".
BRPI0509127A (pt) agentes terapêuticos para distúrbios do ouvido interno contendo um antagonista de il-6 como ingredientes ativo
BR0208636A (pt) Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com inf‰ncia
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
EP1907064A4 (en) SYSTEM AND METHOD FOR PRODUCING SURFACE STRUCTURES WITH A DOSING VOLUME HISTOGRAM
MEP10209A (en) Stable emulsion composition
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
MXPA05013758A (es) Composiciones farmaceuticas que incluyen una antihistamina y un estimulante y uso de las mismas.
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
RS20050618A (en) Use of dipyridamole in combination with acetylsalicylic acid and an ngiotensin ii antagonist for stroke prevention
CO5690618A2 (es) Agente terapeutico para el mesotelioma
EA200501818A1 (ru) Индазолы, обладающие анальгетической активностью
NO20065473L (no) IL-6RL/IL-6-kimaerer for terapi av kjemoterapeutisk indusert perifer nevropati.
ECSP055992A (es) Composición espermicidal y/o antifungica y metodos de uso de la misma
HK1103027A1 (en) 4-hydroxy tamoxifen gel formulations
ATE361092T1 (de) Verwendung des follikel stimulierenden hormons zur reduzierung von chromosomalen aberrationen der spermatozoen in mann
ITMI20040145A1 (it) L-moprololo lpiu' tartrato

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.